<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38801034</PMID><DateCompleted><Year>2024</Year><Month>05</Month><Day>27</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1936-9018</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>3</Issue><PubDate><Year>2024</Year><Month>May</Month></PubDate></JournalIssue><Title>The western journal of emergency medicine</Title><ISOAbbreviation>West J Emerg Med</ISOAbbreviation></Journal><ArticleTitle>Addressing System and Clinician Barriers to Emergency Department-initiated Buprenorphine: An Evaluation of Post-intervention Physician Outcomes.</ArticleTitle><Pagination><StartPage>303</StartPage><EndPage>311</EndPage><MedlinePgn>303-311</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.5811/westjem.18320</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="UNASSIGNED">Emergency departments (ED) are in the unique position to initiate buprenorphine, an evidence-based treatment for opioid use disorder (OUD). However, barriers at the system and clinician level limit its use. We describe a series of interventions that address these barriers to ED-initiated buprenorphine in one urban ED. We compare post-intervention physician outcomes between the study site and two affiliated sites without the interventions.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">This was a cross-sectional study conducted at three affiliated urban EDs where the intervention site implemented OUD-related electronic note templates, clinical protocols, a peer navigation program, education, and reminders. Post-intervention, we administered an anonymous, online survey to physicians at all three sites. Survey domains included demographics, buprenorphine experience and knowledge, comfort with addressing OUD, and attitudes toward OUD treatment. Physician outcomes were compared between the intervention site and the control sites with bivariate tests. We used logistic regression controlling for significant demographic differences to compare physicians' buprenorphine experience.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Of 113 (51%) eligible physicians, 58 completed the survey: 27 from the intervention site, and 31 from the control sites. Physicians at the intervention site were more likely to spend &lt;75% of their work week in clinical practice and to be in medical practice for &lt;7&#xa0;years. Buprenorphine knowledge (including status of buprenorphine prescribing waiver), comfort with addressing OUD, and attitudes toward OUD treatment did not differ significantly between the sites. Physicians were 4.5 times more likely to have administered buprenorphine at the intervention site (odds ratio [OR] 4.5, 95% confidence interval 1.4-14.4, <i>P</i>&#x2009;=&#x2009;0.01), which remained significant after adjusting for clinical time and years in practice, (OR 3.5 and 4.6, respectively).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">Physicians exposed to interventions addressing system- and clinician-level implementation barriers were at least three times as likely to have administered buprenorphine in the ED. Physicians' buprenorphine knowledge, comfort with addressing and attitudes toward OUD treatment did not differ significantly between sites. Our findings suggest that ED-initiated buprenorphine can be facilitated by addressing implementation barriers, while physician knowledge, comfort, and attitudes may be harder to improve.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mahal</LastName><ForeName>Jacqueline J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Jacobi Medical Center, Department of Emergency Medicine, Bronx, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Albert Einstein College of Medicine, Department of Emergency Medicine, Bronx, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bijur</LastName><ForeName>Polly</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Albert Einstein College of Medicine, Department of Emergency Medicine, Bronx, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sloma</LastName><ForeName>Audrey</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Jacobi Medical Center, Department of Emergency Medicine, Bronx, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Starrels</LastName><ForeName>Joanna</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Albert Einstein College of Medicine/Montefiore Medical Center, Department of Medicine, Bronx, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Tiffany</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Jacobi Medical Center, Department of Psychiatry &amp; Behavioral Sciences, Bronx, New York.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K24 DA046309</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RM1 DA055437</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>West J Emerg Med</MedlineTA><NlmUniqueID>101476450</NlmUniqueID><ISSNLinking>1936-900X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>40D3SCR4GZ</RegistryNumber><NameOfSubstance UI="D002047">Buprenorphine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009292">Narcotic Antagonists</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002047" MajorTopicYN="Y">Buprenorphine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004636" MajorTopicYN="Y">Emergency Service, Hospital</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009293" MajorTopicYN="Y">Opioid-Related Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058850" MajorTopicYN="Y">Opiate Substitution Treatment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010818" MajorTopicYN="Y">Practice Patterns, Physicians'</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009292" MajorTopicYN="Y">Narcotic Antagonists</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001291" MajorTopicYN="N">Attitude of Health Personnel</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010820" MajorTopicYN="N">Physicians</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><i>Conflicts of Interest</i>: By the <i>West</i>JEM article submission agreement, all authors are required to disclose all affiliations, funding sources and financial or management relationships that could be perceived as potential sources of bias. No author has professional or financial relationships with any companies that are relevant to this study. There are no conflicts of interest or sources of funding to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>5</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>1</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>1</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>5</Month><Day>27</Day><Hour>12</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>5</Month><Day>27</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>5</Month><Day>27</Day><Hour>6</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>5</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38801034</ArticleId><ArticleId IdType="pmc">PMC11112658</ArticleId><ArticleId IdType="doi">10.5811/westjem.18320</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>
Ahmad FB, Cisewski JA, Rossen LM, et al. . Provisional drug overdose death counts. National Center for Health Statistics. 2023. Available at: https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm. Accessed November 20, 2023.</Citation></Reference><Reference><Citation>Goldman-Mellor S, Olfson M, Lidon-Moyano C, et al. . Mortality following nonfatal opioid and sedative/hypnotic drug overdose. Am J Prev Med. 2020;59(1):59&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7311279</ArticleId><ArticleId IdType="pubmed">32389530</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Onofrio G, O&#x2019;Connor PG, Pantalon MV, et al. . Emergency department-initiated buprenorphine/naloxone treatment for opioid dependence: A randomized clinical trial. JAMA. 2015;313(16):1636&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4527523</ArticleId><ArticleId IdType="pubmed">25919527</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaucher KA, Caruso EH, Sungar G, et al. . Evaluation of an emergency department buprenorphine induction and medication-assisted treatment referral program. Am J Emerg Med. 2020;38(2):300&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">31387811</ArticleId></ArticleIdList></Reference><Reference><Citation>Edwards FJ, Wicelinski R, Gallagher N, et al. . Treating opioid withdrawal with buprenorphine in a community hospital emergency department: an outreach program. Ann Emerg Med. 2020;75(1):49&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">31732373</ArticleId></ArticleIdList></Reference><Reference><Citation>
Substance Abuse and Mental Health Services Administration (SAMHSA) . Use of Medication-Assisted Treatment in Emergency Departments. 2021. Available at: https://store.samhsa.gov/sites/default/files/pep21-pl-guide-5.pdf. Accessed August 16, 2023.</Citation></Reference><Reference><Citation>Hawk K, Hoppe J, Ketcham E, et al. . Consensus recommendations on the treatment of opioid use disorder in the emergency department. Ann Emerg Med. 2021;78(3):434&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">34172303</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhee TG, D&#x2019;Onofrio G, Fiellin DA. Trends in the use of buprenorphine in US emergency departments, 2002&#x2013;2017. JAMA Netw Open. 2020;3(10):e2021209.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7576404</ArticleId><ArticleId IdType="pubmed">33079195</ArticleId></ArticleIdList></Reference><Reference><Citation>Hawk KF, D&#x2019;Onofrio G, Chawarski MC, et al. . Barriers and facilitators to clinician readiness to provide emergency department-initiated buprenorphine. JAMA Netw Open. 2020;3(5):e204561.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7215257</ArticleId><ArticleId IdType="pubmed">32391893</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendiola CK, Galetto G, Fingerhood M. An exploration of emergency physicians&#x2019; attitudes toward patients with substance use disorder, J Addict Med. March/April 2018;12(2):132&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">29351141</ArticleId></ArticleIdList></Reference><Reference><Citation>Lowenstein M, Kilaru A, Perrone J, et al. . Barriers and facilitators for emergency department initiation of buprenorphine: a physician survey. Am J Emerg Med. 2019;37(9):1787&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7556325</ArticleId><ArticleId IdType="pubmed">30803850</ArticleId></ArticleIdList></Reference><Reference><Citation>Savage T, Ross M. Barriers and attitudes reported by Canadian emergency physicians regarding the initiation of buprenorphine/naloxone in the emergency department for patients with opioid use disorder. CJEM. 2022;24(1):44&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">34564838</ArticleId></ArticleIdList></Reference><Reference><Citation>Logan G, Mirajkar A, Houck J, et al. . Physician-perceived barriers to treating opioid use disorder in the emergency department. Cureus. 2021;13(11):e19923.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8710303</ArticleId><ArticleId IdType="pubmed">34966614</ArticleId></ArticleIdList></Reference><Reference><Citation>Foster SD, Lee K, Edwards C, et al. . Providing incentive for emergency physician X-waiver training: an evaluation of program success and postintervention buprenorphine prescribing. Ann Emerg Med. 2020;76(2):206&#x2013;214.</Citation><ArticleIdList><ArticleId IdType="pubmed">32376089</ArticleId></ArticleIdList></Reference><Reference><Citation>Butler K, Chavez T, Wakeman S, et al. . Nudging emergency department-initiated addiction treatment. J Addict Med. 2022;16(4):e234&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">34775439</ArticleId></ArticleIdList></Reference><Reference><Citation>Khatri U, Lee K, Lin T, et al. . A brief educational intervention to increase ED initiation of buprenorphine for opioid use disorder (OUD). J Med Toxicol. 2022;18(3):205&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9004452</ArticleId><ArticleId IdType="pubmed">35415804</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Onofrio G, Edelman EJ, Hawk KF, et al. . Implementation facilitation to promote emergency department-initiated buprenorphine for opioid use disorder: protocol for a hybrid type III effectiveness-implementation study (Project ED HEALTH). Implement Sci. 2019;14(1):48.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6505286</ArticleId><ArticleId IdType="pubmed">31064390</ArticleId></ArticleIdList></Reference><Reference><Citation>Whiteside LK, D&#x2019;Onofrio G, Fiellin DA, et al. . Models for implementing emergency department-initiated buprenorphine with referral for ongoing medication treatment at emergency department discharge in diverse academic centers. Ann Emerg Med. 2022;80(5):410&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9588652</ArticleId><ArticleId IdType="pubmed">35752520</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Onofrio G, Edelman EJ, Hawk KF, et al. . Implementation facilitation to promote emergency department&#x2013;initiated buprenorphine for opioid use disorder. JAMA Netw Open. 2023;6(4):e235439.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10077107</ArticleId><ArticleId IdType="pubmed">37017967</ArticleId></ArticleIdList></Reference><Reference><Citation>
Tuazon E, Bauman M, Sun T, et al. . Unintentional Drug Poisoning (Overdose) Deaths in New York City in 2022. New York City Department of Health and Mental Hygiene: Epi Data Brief (137); September 2023. Available at: https://www.nyc.gov/assets/doh/downloads/pdf/epi/databrief137.pdf. Accessed February 13, 2024.</Citation></Reference><Reference><Citation>
Centers for Medicare and Medicaid Services . Quality Measurement and Quality Improvement. 2023. Available at: https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/MMS/Quality-Measure-and-Quality-Improvement-. Accessed November 23, 2023.</Citation></Reference><Reference><Citation>Martin A, Kunzler N, Nakagawa J, et al. . Get waivered: a resident-driven campaign to address the opioid overdose crisis. Ann Emerg Med. 2019;74(5):691&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">31272821</ArticleId></ArticleIdList></Reference><Reference><Citation>Wood K, Giannopoulos V, Louie E, et al. . The role of clinical champions in facilitating the use of evidence-based practice in drug and alcohol and mental health settings: a systematic review. Implement Res and Pract. 2020;1:2633489520959072.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9924254</ArticleId><ArticleId IdType="pubmed">37089122</ArticleId></ArticleIdList></Reference><Reference><Citation>Im DD, Chary A, Condella AL, et al. . Emergency department clinicians&#x2019; attitudes toward opioid use disorder and emergency department-initiated buprenorphine treatment: a mixed-methods study. West J Emerg Med. 2020;21(2):261&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7081867</ArticleId><ArticleId IdType="pubmed">32191184</ArticleId></ArticleIdList></Reference><Reference><Citation>Sokol R, Tammaro E, Kim JY, et al. . Linking MATTERS: barriers and facilitators to implementing emergency department-initiated buprenorphine-naloxone in patients with opioid use disorder and linkage to long-term care. Subst Use Misuse. 2021;56(7):1045&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">33825669</ArticleId></ArticleIdList></Reference><Reference><Citation>
Office of National Drug Control Policy (ONDCP) . Dr. Gupta applauds removal of X-waiver in omnibus, urges healthcare providers to treat addiction. 2022. Available at: https://www.whitehouse.gov/ondcp/briefing-room/2022/12/30/dr-gupta-applauds-removal-of-x-waiver-in-omnibus-urges-healthcare-providers-to-treat-addiction. Accessed February 23, 2023.</Citation></Reference><Reference><Citation>US Department of Justice, Drug Enforcement Administration, Diversion Control Division. Elimination of the DATA waiver program. Available at: https://www.deadiversion.usdoj.gov/pubs/docs/dear_registrant_AM_01122023.html. Accessed November 20, 2023.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>